Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to ...

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

Qure (QURE) is back on traders’ radar after a sharp 9% one day decline, prompting fresh attention on how its gene therapy ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is one of the stocks under $1 that will explode. Sangamo Therapeutics, Inc.’s (NASDAQ:SGMO) share price has underperformed over the past year, down nearly 64%.

Key market opportunities in cell and gene therapy include tracking investment trends, analyzing key deals, and staying updated with scientific developments and market forecasts. The publication is ...

To discover more about Nature’s Fynd, visit. To learn about their remarkable nutritional fungi protein and fermentation ...

US biotech firm Fractyl Health is developing Rejuva, an experimental gene therapy that may mimic GLP-1 drugs for years after ...